Table 3.
Comparisons of demographic and clinical characteristics as well as CTC status, CTC count, and PFS and OS between 4 subgroups corresponding to therapeutically relevant receptor dynamics.
| Statistics | ER + HER2 Ø > ER + HER2 Ø |
ER Ø HER2 Ø > ER Ø HER2 Ø |
ER + HER2 + > ER Ø HER2 Ø |
Other | p |
|---|---|---|---|---|---|
| Total, n (%) | 138 (100%) | 35 (100%) | 19 (100%) | 69 (100%) | |
| CTC positive, n (%) | 53 (38.4%) | 14 (40%) | 8 (42.1%) | 15 (21.7%) | 0.08 |
| CTC count, median (range) | 1 (0–200,000) | 1 (0–74) | 3 (0–840) | 0 (0–840) | 0.10 |
| Age at initial diagnosis, median (range) |
50 (43–87) | 51 (33–68) | 44 (33–66) | 48 (23–69) | 0.008 |
| Age at enrollment, median (range) |
59 (24–87) | 52 (35–74) | 50 (35–78) | 53 (29–63) | 0.005 |
| Number of metastatic sites | 0.70 | ||||
| One site, n (%) | 31 (22.5%) | ||||
| Multiple sites, n (%) | 107 (77.5%) | ||||
| Site of metastasis | |||||
| Bone, n (%) | 93 (67.4%) | 11 (31.4%) | 11 (57.9%) | 38 (57.9%) | 0.002 |
| Visceral, n (%) | 113 (81.9%) | 29 (82.9%) | 15 (78.9%) | 56 (81.2%) | 0.99 |
| Metastatic therapy | |||||
| First line, n (%) | 18 (13%) | 4 (11.4%) | 4 (21.1%) | 9 (13%) | 0.4 |
| Second, n (%) | 45 (32.6%) | 14 (40%) | 7 (36.8%) | 15 (21.7%) | |
| Other, n (%) | 75 (54.3%) | 17 (48.6%) | 8 (42.1%) | 45 (65.2%) | |
| Metastatic chemotherapy | |||||
| First line, n (%) | 48 (34.8%) | 8 (22.9%) | 6 (31.6%) | 16 (23.2%) | 0.048 |
| Second, n (%) | 45 (32.6%) | 12 (34.3%) | 7 (36.8%) | 14 (20.3%) | |
| Other, n (%) | 45 (32.6%) | 15 (42.9%) | 6 (31.6%) | 39 (56.6%) | |
| PFS, median (range) | 6 (1–76) | 4.5 (0–18) | 5 (0–19) | 4 (0–32) | 0.6 |
| OS, median (range) | 20.5 (0–94) | 11 (0–94) | 10 (0–29.5) | 18 (0–92) | 0.07 |
Ø—negative; ER—estrogen receptor; HER2—human epidermal growth factor receptor 2.